Concept Medical
Concept Medical has initiated the “MAGICAL-ISR” IDE clinical study in the US, utilizing the MagicTouch Sirolimus drug-coated balloon (DCB) for in-stent restenosis (ISR) management.
The study, granted ‘Breakthrough Device’ designation and FDA Investigational Device Exemption (IDE) approval, aims to evaluate the safety and efficacy of MagicTouch in treating ISR. Led by renowned physicians, the study focuses on patients avoiding Target Lesion Failure (TLF) within one year post-procedure.
MagicTouch offers controlled Sirolimus release without permanent scaffold implantation, marking a significant advancement in coronary intervention. This development reflects Concept Medical’s commitment to innovation and patient care.
Dr Manish Doshi, Founder & Managing Director of Concept Medical says, “The MagicTouch technology has been embraced globally, and its entry into the US market through this study, represents a critical step towards addressing the unmet needs in ISR treatment. Our commitment to innovation and patient safety is unwavering, and we anticipate this study will significantly impact how ISR is treated worldwide.”
Read More Business News
Lembaga Tabung Haji has improved its financial position through recovery efforts, enhancing asset quality and…
Schroders Capital's Q3 2026 outlook highlights private markets' resilience and the need for selective, deliberate…
Kinergy initiated with BUY, TP RM0.67, driven by recurring income, engineering services growth, and unpriced…
PETALING JAYA, 22 July 2026 – LOCUS-T, a leading Malaysian digital marketing agency, has been…
German investor sentiment rose sharply in July, boosted by reform optimism, although geopolitical tensions and…
The FBM KLCI eased despite a strong technology rebound as investors shifted focus to Alphabet…
This website uses cookies.
